T3D Therapeutics

Executive Summary

T3D Therapeutics, founded in 2013 and headquartered in Research Triangle Park, NC, is a private biopharmaceutical company developing disease-modifying small molecule therapies for Alzheimer's disease (AD) and other neurodegenerative conditions, including Huntington's disease. Its lead candidate, T3D-959, is a nuclear receptor agonist designed to address metabolic dysfunction and neuroinflammation, key pathologies in AD. Currently in Phase 2 clinical trials, T3D-959 targets an underexplored mechanism distinct from amyloid- and tau-focused approaches, potentially offering a differentiated therapeutic option. The company's pipeline also includes preclinical programs for Huntington's disease. With no approved disease-modifying treatments for AD, T3D Therapeutics represents a high-risk, high-reward opportunity if its metabolic approach proves effective in ongoing trials. However, as a private company with limited public data, the near-term visibility of catalysts is constrained, and success hinges on positive Phase 2 data.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data readout for T3D-959 in Alzheimer's disease30% success
• H1 2027Initiation of Phase 2 trial for T3D-959 in Huntington's disease40% success
• TBDPotential partnership or licensing deal for T3D-959 or platform25% success